View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsQuia Pharma 배당 및 자사주 매입배당 기준 점검 0/6Quia Pharma 배당금을 지급한 기록이 없습니다.핵심 정보0%배당 수익률238.1%자사주 매입 수익률총 주주 수익률238.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향0%최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • May 27Quia Pharma AB (publ), Annual General Meeting, Jun 26, 2025Quia Pharma AB (publ), Annual General Meeting, Jun 26, 2025, at 10:30 W. Europe Standard Time. Location: at the premises of maqs advokatbyra, address stureplan 19, stockholm SwedenBoard Change • Oct 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Chairman of the Board Per Thoresen was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Feb 27Full year 2023 earnings released: kr0.034 loss per share (vs kr11.34 loss in FY 2022)Full year 2023 results: kr0.034 loss per share (improved from kr11.34 loss in FY 2022). Revenue: kr4.39m (down 21% from FY 2022). Net loss: kr16.5m (loss narrowed 18% from FY 2022).Reported Earnings • Aug 23First half 2023 earnings released: kr0.015 loss per share (vs kr9.45 loss in 1H 2022)First half 2023 results: kr0.015 loss per share (improved from kr9.45 loss in 1H 2022). Revenue: kr1.75m (down 33% from 1H 2022). Net loss: kr9.84m (loss narrowed 2.6% from 1H 2022).Reported Earnings • Nov 26Third quarter 2022 earnings released: kr0.022 loss per share (vs kr0.079 loss in 3Q 2021)Third quarter 2022 results: kr0.022 loss per share. Revenue: kr1.64m (down 31% from 3Q 2021). Net loss: kr5.19m (loss widened 8.2% from 3Q 2021).Reported Earnings • Aug 25Second quarter 2022 earnings released: kr0.032 loss per share (vs kr0.076 loss in 2Q 2021)Second quarter 2022 results: kr0.032 loss per share. Revenue: kr1.46m (down 43% from 2Q 2021). Net loss: kr4.74m (loss widened 5.4% from 2Q 2021).Reported Earnings • May 26First quarter 2022 earnings released: kr0.063 loss per share (vs kr0.066 loss in 1Q 2021)First quarter 2022 results: kr0.063 loss per share. Revenue: kr1.15m (down 54% from 1Q 2021). Net loss: kr5.36m (loss widened 41% from 1Q 2021).Reported Earnings • Feb 28Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.32 loss per share (up from kr0.67 loss in FY 2020). Revenue: kr8.73m (up 134% from FY 2020). Net loss: kr20.0m (loss narrowed 28% from FY 2020). Revenue was in line with analyst estimates.Reported Earnings • Dec 01Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.079 loss per share (up from kr0.26 loss in 3Q 2020). Revenue: kr2.38m (up 300% from 3Q 2020). Net loss: kr4.80m (loss narrowed 50% from 3Q 2020). Revenue was in line with analyst estimates.Reported Earnings • Aug 28Second quarter 2021 earnings released: kr0.076 loss per share (vs kr0.18 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: kr2.58m (flat on 2Q 2020). Net loss: kr4.50m (loss narrowed 23% from 2Q 2020).Reported Earnings • May 28First quarter 2021 earnings released: kr0.066 loss per shareThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: kr2.49m (up kr2.45m from 1Q 2020). Net loss: kr3.81m (loss narrowed 34% from 1Q 2020).Reported Earnings • Mar 01Full year 2020 earnings released: kr0.87 loss per share (vs kr0.63 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr3.74m (down 16% from FY 2019). Net loss: kr27.7m (loss widened 42% from FY 2019).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 99B0 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 99B0 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Quia Pharma 배당 수익률 vs 시장99B0의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (99B0)0%시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.6%업계 평균 (Biotechs)2.2%분석가 예측 (99B0) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 99B0 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 99B0 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 99B0 German 시장에서 주목할만한 배당금을 지급하지 않습니다.주주 현금 배당현금 흐름 범위: 99B0 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/16 20:37종가2025/11/20 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Quia Pharma AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • May 27Quia Pharma AB (publ), Annual General Meeting, Jun 26, 2025Quia Pharma AB (publ), Annual General Meeting, Jun 26, 2025, at 10:30 W. Europe Standard Time. Location: at the premises of maqs advokatbyra, address stureplan 19, stockholm Sweden
Board Change • Oct 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Chairman of the Board Per Thoresen was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Feb 27Full year 2023 earnings released: kr0.034 loss per share (vs kr11.34 loss in FY 2022)Full year 2023 results: kr0.034 loss per share (improved from kr11.34 loss in FY 2022). Revenue: kr4.39m (down 21% from FY 2022). Net loss: kr16.5m (loss narrowed 18% from FY 2022).
Reported Earnings • Aug 23First half 2023 earnings released: kr0.015 loss per share (vs kr9.45 loss in 1H 2022)First half 2023 results: kr0.015 loss per share (improved from kr9.45 loss in 1H 2022). Revenue: kr1.75m (down 33% from 1H 2022). Net loss: kr9.84m (loss narrowed 2.6% from 1H 2022).
Reported Earnings • Nov 26Third quarter 2022 earnings released: kr0.022 loss per share (vs kr0.079 loss in 3Q 2021)Third quarter 2022 results: kr0.022 loss per share. Revenue: kr1.64m (down 31% from 3Q 2021). Net loss: kr5.19m (loss widened 8.2% from 3Q 2021).
Reported Earnings • Aug 25Second quarter 2022 earnings released: kr0.032 loss per share (vs kr0.076 loss in 2Q 2021)Second quarter 2022 results: kr0.032 loss per share. Revenue: kr1.46m (down 43% from 2Q 2021). Net loss: kr4.74m (loss widened 5.4% from 2Q 2021).
Reported Earnings • May 26First quarter 2022 earnings released: kr0.063 loss per share (vs kr0.066 loss in 1Q 2021)First quarter 2022 results: kr0.063 loss per share. Revenue: kr1.15m (down 54% from 1Q 2021). Net loss: kr5.36m (loss widened 41% from 1Q 2021).
Reported Earnings • Feb 28Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.32 loss per share (up from kr0.67 loss in FY 2020). Revenue: kr8.73m (up 134% from FY 2020). Net loss: kr20.0m (loss narrowed 28% from FY 2020). Revenue was in line with analyst estimates.
Reported Earnings • Dec 01Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: kr0.079 loss per share (up from kr0.26 loss in 3Q 2020). Revenue: kr2.38m (up 300% from 3Q 2020). Net loss: kr4.80m (loss narrowed 50% from 3Q 2020). Revenue was in line with analyst estimates.
Reported Earnings • Aug 28Second quarter 2021 earnings released: kr0.076 loss per share (vs kr0.18 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses and improved control over expenses, although revenues were flat. Second quarter 2021 results: Revenue: kr2.58m (flat on 2Q 2020). Net loss: kr4.50m (loss narrowed 23% from 2Q 2020).
Reported Earnings • May 28First quarter 2021 earnings released: kr0.066 loss per shareThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: kr2.49m (up kr2.45m from 1Q 2020). Net loss: kr3.81m (loss narrowed 34% from 1Q 2020).
Reported Earnings • Mar 01Full year 2020 earnings released: kr0.87 loss per share (vs kr0.63 loss in FY 2019)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: kr3.74m (down 16% from FY 2019). Net loss: kr27.7m (loss widened 42% from FY 2019).